C-J0SDKatairo GmbH
lipofuscin removal, retinal pigment epithelium, ophthalmology
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-J0SD
C-J0SDC-J0SDlipofuscin removal, retinal pigment epithelium, ophthalmology
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Isma ne maama we bakera saawa kumi ( 10) kulongosa kibuga | Hon Namugga Gorreth
%PDF-1.6 %���� 29445 0 obj >stream hތSmO�0�+�X4��c�I$����V�HY� L���8�]���K;��i���=���|~����(AiIi� F�pZ � G�����(0:;�j�}�\� L����$K�~� � Z���gp��w0�����������BV�43n~8j/`�6�x����V@�C�b^�_s#���P�_��O�ZK>��;Y�n}�V���R�Uo� *���-��k��[-�����P_���q�����|c꾗����� ��rhh)Wvk SJ]�__V����1��� H��+���˰�%�4XK�p� ��,���g����E����|�)ޯiEo�pc>\ ��ZĊ��aG`� �%��S�Z��` ZX��5l` :�A �`����+*�?M�i�7�xWu�^ Oi�B � �������FA ȩy5 /�����&A���;� >stream h�2��0V0P�6�4432��,S 8� ˚�eML�,c�, `�v endstream endobj 29447 0 obj >stream h�2��0Q0P����M-ILI,IT0��� V�� endst … � ���a/��M�0#��ءq��� ��sܖ�P���c��)�lh@U �*(/R�Br���z�cxu�\�]��{{_9� >stream application/pdf figure 2.1 malaria cases per region and countries 2025 2025-11-25T23:28:47+01:00 2025-11-25T23:28:47+01:00 2025-11-25T23:28:47+01:00 Adobe Illustrator 30.0 (Macintosh) uuid:5780adfd-bde7-aa46-ac14-7487fcc4d017 xmp.did:e6b6db1d-ed08-4b9d-943a-22c1383d9909 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:0869659e-833e-8d49-9f44-adc11d3ff1ce xmp.did:85f364f8-b1f9-42e7-9dcb-5eebd21 … ` �7��wu�ٽ�o�|����,y�r�-�'|�)�BmG�0��o� endstream endobj 79 0 obj >stream application/pdf figure 2.2 2025 legend 2025-11-07T10:34:45+01:00 2025-11-07T10:34:45+01:00 2025-11-07T10:34:45+01:00 Adobe Illustrator 30.0 (Macintosh) uuid:f2517c55-1c6c-544b-b7be-2a25c0c7ef1e xmp.did:d92fda82-1c7f-46d7-beb9-f956f54cdad1 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:c2da64de-69c7-1241-9132-1561e84d9d2d xmp.did:7bf6dd83-e4b4-446c-908f-59d0af94dafc uuid:5D20892493BFDB11914A8 … ` �7��wu�ٽ�o�|����,y�r�-�'|�)�BmG�0��o� endstream endobj 89 0 obj >stream application/pdf figure 2.3a cases 2025 2025-11-11T13:57:18+01:00 2025-11-11T13:57:18+01:00 2025-11-11T13:57:18+01:00 Adobe Illustrator 30.0 (Macintosh) uuid:20cb3fc5-2025-ac4e-a0ef-ff25330fb4ba xmp.did:ea2a7ad4-ddee-4d4d-9f71-c356c49c35d7 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:ff014f0d-d7a9-9144-94ea-ea1d033b22d8 xmp.did:757a0377-2055-4243-b789-89d4a898f3dd uuid:5D20892493BFDB11914A8 … 000 0.000000 0.000000 Adobe PDF library 17.00 endstream endobj 90 0 obj >stream application/pdf figure 2.3b deaths 2025 2025-11-25T23:34:03+01:00 2025-11-25T23:34:03+01:00 2025-11-25T23:34:03+01:00 Adobe Illustrator 30.0 (Macintosh) uuid:5c34b156-2f07-b14b-b2e5-ef5f5f58959b xmp.did:f5d23d67-0aac-4ed4-bac1-2bddcb943bcc uuid:5D20892493BFDB11914A859
%PDF-1.7 %���� 36570 0 obj > endobj 36584 0 obj >/Filter/FlateDecode/ID[ ]/Index[36570 40]/Info 36569 0 R/Length 91/Prev 7827650/Root 36571 0 R/Size 36610/Type/XRef/W[1 3 1]>>stream h�bbd```b`��"�@$s"��"�XIƍwA��� ���@��� r�'�H��& H�\�$���0012�e�d�� �?C��K��tT endstream endobj startxref 0 %%EOF 36609 0 obj >stream h��Z TSg��ߛ���y�&b��O�E���i|!R[�Ri�մ��\B��W��N@���ST�`u�D��em��A�� J���t���ծ������N;�g�l�4�$����������ߜ 8# �����{ ? �L`kkd�ԅ���>y�Y��Mʦ~t��c1�Ϛq�� ���ۇ�bRNIʍyl�y ��Y5��/N���up��w�� ë�$�������X� �P \ѱ� Ռ�K��G�^2�r`Z��Է�2��� �$6]�� &б�!G�3��I�qdX� … ������NHw�p�$����^&�mkC�o5����[4R\�y��bhp�F%6�LQ��r��%ރ]c�{�� o ��������]rfp�����쳝S8A�c;"�WҊ����ɒ6�0?���"NB�����ѭ�y\���І�4�R� |�@�~�.�� ��fL���~� �w�� ��ڿr�f�o_������`nZd�kQd2�u�xG��%ZjA�l.��F�j���FUZh�� � �Z ��v9�he����z`�q�#����7�`c{:f�� �ʶ�ŋ�3�����4����W���+����_�W�MA@S���jUB��0pd��=z �輫����9J��mt�PӾٹ���[m߄�Q�1ѹ��ֱ��ٕ-��A+[�d��?�\����U�� ���r���i�]ѻ��䈕�|�Rh�+N� B;}u��# \��%��Ƙ�A���K�������lp���r��a���?3$M���'����d��~UA��ڂhk��F�w�� k]�% … ONE 7489 C SPOT 100.000000 CMYK 63.529402 14.117600 99.607801 1.176500 Document application/pdf avacareLogopaths proof:pdf xmp.did:1D4C24E8F5FDE41184E9B38F7C4482D8 uuid:ed3f2c21-1c91-46ee-9b2b-ca68be57d533 uuid:b32019bd-ce1a-4490-a2aa-b1f16c268e24 uuid:09bd0599-e2c4-4826-be2a-2348619c04f3 xmp.did:1E0D8B0B555BE411A4A0CE599C6FE200 uuid:b32019bd-ce1a-4490-a2aa-b1f16c268e24 proof:pdf saved xmp.iid:5E2F09929DF0E31198F6DEE190089157 2014-06-11T09:49:16+02:00 Adobe Illustrator CS6 (W … rator CS6 (Windows) / Adobe PDF library 10.01 endstream endobj 26 0 obj >stream application/postscript Print MacPro2 2011-10-10T09:54:33-07:00 2011-10-10T09:54:33-07:00 2011-10-10T09:54:33-07:00 Adobe Illustrator CS5 xmp.iid:02801174072068118A6DECD8A91FDB2F xmp.did:02801174072068118A6DECD8A91FDB2F uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:01801174072068118A6DECD8A91FDB2F xmp.did:01801174072068118A6DECD8A91FDB2F uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf sav … 6DECD8A91FDB2F 2011-10-10T09:54:33-07:00 Adobe Illustrator CS5 / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator Print True False 1 595.280273 841.889648 Points Magenta Ye
%PDF-1.5 %���� 1 0 obj >>> endobj 2 0 obj >stream 2023-05-23T13:09:42-07:00 2023-05-23T13:13:01-07:00 2023-05-23T13:13:01-07:00 Adobe InDesign 14.0 (Windows) uuid:4111844e-b823-45ae-8ff4-d471e1baff9b xmp.did:af514e8a-f7ea-ec45-bf78-35b73a16df0f xmp.id:5a0d9fdb-44a2-314c-82f5-b5fcaecbaeca proof:pdf converted from application/x-indesign to application/pdf Adobe InDesign CC 14.0 (Windows) / 2023-05-23T13:09:43-07:00 xmp.iid:c8cb33d3-4698-564d-bed1-ad163150ffb9 xmp.did:af514e8a-f7ea-ec45-bf78-35b73a16df0f xmp.did:af514e8a-f7ea-ec45-bf78-35b73a16df0f default application/pdf Adobe PDF Library 15.0 F … ��r84n�#!x���maF������U endstream endobj 103 0 obj > endobj 143 0 obj >stream application/pdf CHS COVER 2 2023-05-21T23:38:14-07:00 2023-05-21T23:38:14-07:00 2023-05-21T15:42:33-07:00 Adobe Illustrator CC 23.0 (Windows) uuid:1e34c8a4-b7e1-48f9-bb3e-3299efee0ac4 xmp.did:ee32b01d-33b6-6442-b033-587975114359 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:9e1425f4-1447-9743-9c60-a5ac14e68531 xmp.did:9e1425f4-1447-9743-9c60-a5ac14e68531 uuid:5D20892493BFDB11914A8590D315 … eam endobj 991 0 obj >stream ��C��B��A�A�@��?�>�>�=� > endobj 992 0 obj >stream application/pdf MAK Emblem final Adobe Illustrator CS3 2013-03-20T13:10:11+04:00 2013-03-20T13:10:11+03:00 2013-03-20T13:10:11+03:00 uuid:43E0AA782F91E2118DCEF5A7344AC6C9 uuid:3c065245-683b-46e2-a03d-3a72e8a83645 uuid:d88b5f42-4c96-412f-acda-5c9fe16b8f0d uuid:31528546D947DF1198E1B27BB84EC417 Print 1 True False 41.999995 29.700000 Centimeters Cyan Magenta Yellow Black PANTONE 376 C Default Swatch G … �9��:�;� ��?��@��A��B��C endstream endobj 850 0 obj > endobj 1056 0 obj >stream application/pdf CHS COVER 2 2023-05-21T23:38:14-07:00 2023-05-21T23:38:14-07:00 2023-05-21T15:42:33-07:00 Adobe Illustrator CC 23.0 (Windows) uuid:1e34c8a4-b7e1-48f9-bb3e-3299efee0ac4 xmp.did:ee32b01d-33b6-6442-b033-587975114359 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:9e1425f4-1447-9743-9c60-a5ac14e68531 xmp.did:9e1425f4-1447-9743-9c60-a5ac14e68531 uuid:5D20892493BFDB11914A8590D315
Scientific Journals COVID answers in Scientific Journals all over the world 804254 Results Page 39 [ < Back ] [ 37 ] [ 38 ] [39] [ 40 ] [ 41 ] [ Next > ] Date original article Publishing House Journal Title Authors All Authors 76001 2024―Dec―26 [GO] Yerevan State University Journal of Sociology Bulletin of Yerevan University EXPLORING THE IMPACT OF COVID-19 PANDEMIC ON THE MENTAL HEALTH OF NGO STAFF IN BANGLADESH, FOCUSING ON STRESS AND C … deological Diversity of Media Consumption Predicts COVID-19 Vaccination Marissa Grant, David Markowitz, David Sherman, Alex Flores, Stephan Dickert, Kimin Eom, et al. (+10) Gabriela Jiga-Boy, Tehila Kogut, Marcus Mayorga, David Oonk, Eric Pedersen, Beatriz Pereira, Enrico Rubaltelli, Paul Slovic, Daniel Västfjäll, Leaf Van Boven 76019 2024―Dec―26 [GO] International Journal of Research and Innovation in Social Science Intern … ournal of Mathematics A Class of Transformed Population Mean Estimators with an Application to Missing COVID-19 Data in Chiang Mai, Thailand Natthapat Thongsak, Nuanpan Lawson 76083 2024―Dec―26 [GO] SPIE - International Society for Optical Engineering Journal of Medical Imaging Impact of retraining and data partitions on the generalizability of a deep learning model in the task of COVID-19 classification on chest radiographs Mena Shenouda, Heather … of COVID-19 and U.S. monetary policy on Bitcoin and stock market volatility: an application of DCC-GARCH model Kamphol Panyagometh 76085 2024―Dec―26 [GO] Scientific and Practical Reviewed Journal Pulmonology PULMONOLOGIYA COVID-19 and interstitial lung diseases N. V. Trushenko, Yu. A. Levina, A. A. Gordeeva, U. V. Panina, F. Z. Babayan, S. N. Avdeev 76086 2024―Dec―26 [GO] Elsevier Current Research in Translational Medici … ropolises During COVID-19 Recovery Phase Using Fine-tuned Large Language Model: Application of Artificial Intelligence (Preprint) Ryuichi Saito, Sho Tsugawa 76324 2024―Dec―24 [GO] Wiley Journal of Forecasting Money Matters: Broad Divisia Money and the Recovery of the US Nominal GDP From the COVID-19 Recession Michael&#
%PDF-1.6 %���� 8412 0 obj > endobj 8469 0 obj >/Filter/FlateDecode/ID[ ]/Index[8412 299]/Info 8411 0 R/Length 235/Prev 30234953/Root 8413 0 R/Size 8711/Type/XRef/W[1 3 1]>>stream h�bbd```b`�� "�@��5��z"�&���Ad� ɘ7�f�LW��u09 ��2B�%D����π�[�� ��0;̾����e� �H �=w6���{�I/n��m0 q�40��q�|[l ���W9�d*��"�&!$�v!�"�H�X�"�9A I��Y,r'��3��&�ۘ6�\��$�n����Ƞ� � %GIj��sG�a��>�6����'�7 \�2Q endstream endobj startxref 0 %%EOF 8710 0 obj >stream h��X T�����&�1n&��@�C�&0� $"P H�H�����-" �$��%�|e� 0 J �JH 4�"�����A��νu����l�}���|����o���O@ƅ `��b�: ��z����6�ޠ�T��"I�J … sh) 2022-01-21T15:55:34+03:00 2022-01-21T15:55:34+03:00 Adobe PDF library 15.00 application/pdf Mak Univ offical emblem 1 False False 202.139997 176.393689 Millimeters Cyan Magenta Yellow Black Default Swatch Group 0 xmp.did:10644a28-0e42-4f5a-8139-232bf8a100b6 uuid:71e822b8-ac14-2a4a-9d91-250e53579bbf xmp.did:b8ce24e3-0f40-4fe1-86ff-b90b9665a95a proof:pdf uuid:870654cd-5da3-a846-a159-3085d669b64a xmp.did:b8ce24e3-0f40-4fe1-86ff-b90b9665a95a xmp.did:b8ce24e3-0f40-4fe1-86ff-b9 … (5*�4ʹ��&�}�Q�#�'L�b]���qV ��Xzc,�iX���im|�[�nr��1*�y�s%$��~U�1 9t�`���jv� rFP��` �Uڷg%\��2����+� n�S�M�s0���ϔ)��AsQ b��m�B{�?ch���[� p�fnn�5 S��Dž ��K)��q���ێL2u!J��.�rƆKQ!RVrNX�NZ[I�Y���"�+9�eɉ��jME�P��]��H��fi����Y�Q���r#�1��g礩iakR�N��xc{�7ʘk� ���m��"Q2ӯ1�SD�N�J�π |�sMFGU+� 1��-1�מ��JE�u��9 %IV���*b��,m�+b %��\����*:V�(� cr�7� 1湽���ǒ@���Q� X� ��0�ڷ�5?��P~Bx�� �YQ�����T�����Zۿ~�Z��9.8��A�v�N���%�%W��1��z:��K�n :�I�'\qn����)���R �I��p� … ��v)a�������!��`ܤ\���7�� �G!�U3TD�Rw��a��Ka�97��ɫ0��á 8 0J�p~�!���(��)���RfP� !]�X�h�~g!�.m6U)WG��@v�:�Q��>8��ˏ�� ���f���~P 8�"�%syQ=���\�k��}͆�GAJH 2�=n}��\V uJ�N�I�ja���}��'��տ�a�I?6���[-VU�%�5 Y������*�h�dk��U+"�R.1���7�E��UZ��闁�Jn� I�c��U��uCJ���� $�ĵ�+��EO���d��DQ��]UC��y�l�+ ��zp�+N�*������|1�N�����8�ӻH�Vdk�e94PW1�q� }N�7�8ZSO淏���%�dE�c���t�yNU��U Z�X�X� #�o2�O(鑬T�Y[n~$��j�I�;��sK�Ġ s|ʚ��m�,�� �d?��X�9��ގh=���\���? �д ���?�� ՎyD … �rw �)� ��8�v��L/�Б��E����|yϻ!s��i��} �[XzS�J�8� ��;��v=�Y�8V�÷�/Q�[��5��*rfp# �6�� ��p����R�2�sk��#��?Zx�y��R� w� i�l�5��i㖄yCx8%;������IISDʨK�qx�'e����V^���s wL%7��]__ ?lF]�.��G���g��Z�Dف�n��J:W���-$����T�֥��p��asG�Ky�[tR6Od}��*3-K�q��fI�1ǃ�I����������{ vV/=���Xg��m�#�H�+',��n��"J����T�"�e:�)��j�ь=����)T�i!�Q �Ҽ���kv
2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease Search Advanced search Analytics About Укр Back 2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease General information Publication type Journal Article DOI 10.1038/s41569-023-00940-9 Journal 2023 , Nature Reviews Cardiology , № 4 , p. 250-263 Publisher Springer Science and Business Media LLC Authors Joselyn Rwebembera, James Marangou, Julius Chacha Mwita, Ana Olga Mocumbi, Cleonice Mota, Emmy Okello, Bruno Nascimento, Lene Thorup, An … Jeemon DOI: 10.1038/s41467-024-55362-z 2025 , Nature Communications , № 1 Application of the New 2023 World Heart Federation Criteria to Rheumatic Heart Disease in the Setting of First Episode of Acute Rheumatic Fever: Predictors for Resolution Journal Article Scopus WoS Crossref: 4 Jacqueline M. Williamson, Gillian A. Whalley, James Marangou, Peter S. Morris, Zhiqiang Wang, Joshua R. Francis, Bo Remenyi Abstract Rheumatic heart disease (RHD) is a chronic complicati
%PDF-1.4 %���� 876 0 obj > endobj xref 876 28 0000000016 00000 n 0000004653 00000 n 0000004719 00000 n 0000004873 00000 n 0000005055 00000 n 0000005855 00000 n 0000006309 00000 n 0000006823 00000 n 0000006860 00000 n 0000007097 00000 n 0000046588 00000 n 0000046819 00000 n 0000047526 00000 n 0000089021 00000 n 0000089252 00000 n 0000090076 00000 n 0000091712 00000 n 0000092058 00000 n 0000112786 00000 n 0000113022 00000 n 0000113589 00000 n 0000113949 00000 n 0000134738 00000 n 0000134978 00000 n 0000135563 00000 n 0000155919 00000 n 0000158627 00000 n 0000000856 00000 n trailer ]/Prev 1312563 … �m�}��* �6���ի��1k�� �bS�ƞW}���>��fE|L���+K�*�C���6l���uH4��%ٜ �뮻�]V#���rFp }���Q���q& =zt�K����7;jԨ(W���y�f 'A� �˗7g�i_��� � � � � � � � � � �(�E �Ν;�oW�� 5�dۿ{������?� 7W$���ݻ�� �����dѢE�A=�� 2�v�2hN�L�,��jT�Zդ/�&�@@@@@@@@@@��H"A����� �Hu�ˁ���O諕I� ӪT���V��#!!2�j��/�gϞ�}����kmO���m2o�8�&� Kc2��� &]m!��{�%7mڤ�Yޥ�^�P�'�j��]��_������c= 渢^�J�ٵJ��-SM�(c�Y���t��� ���n\x���իWW�����{�SE����3`B ����P� … ��K��q�9���b�|��z�J�̘����U|P+�"7�|����~9��S�����������X������� �w~��79�O;2:RfP��:c�/�89�I ��۷���b�udC:O\u�U?�0��8�(�6��Xx�=���ikD;�����Q�l=&\�e�%��dz:��D��?������P��Q���6ܐg��ֈ��o��;�c��>? �Q�>�L������� ������ �8�Q��^��H���C��_��W�r|Nz��fҊ ���\���C����0ϫ�4YN5��J� �����m�vEu�Ϸ�&5'�jJ�Q �Q�`� �&�@�&�� MQ�h*� E��XQ�4E�"����Q�SQhR� j�������~;��}��Ϛ�g�~����wx����Y��gϬ=�ff�SK�f'�z4Bou�g����L�z�;���Q8�M?=�rl r�nM���� Nҿ � �s� �f����u� �K��(�h� … 2022-12-28T14:47:31Z macOS Versión 12.6 (Compilación 21G115) Quartz PDFContext application/pdf Microsoft Word - LeyrePernauteLau_Thesis (DOCUMENTO DEFINITIVO_Corrected).docx uuid:a9e1f5b4-614c-4512-bc7c-0260bc5acf26 uuid:3e06b533-26a8-434c-88ee-dde1ab913681 endstream endobj 875 0 obj > endobj xref 0 876 0000000000 65535 f 0000184160 00000 n 0000184308 00000 n 0000184419 00000 n 0000184705 00000 n 0000184853 00000 n 0000185033 00000 n 0000188264 00000 n 0000188412 00000 n 000
Plastoquinonyl decyl triphenylphosphonium - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 27 Feb 2026 Plastoquinonyl decyl triphenylphosphonium Last update 27 Feb 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Small molecule drug Synonyms Plastomitin, Visomitin, SKQ-1 + [3] Target 50S subunit x Electron transport chain complex proteins Action inhibitors, modulators Mechanism 50S subunit inhibitors(50S ribosomal subunit inhib … ont payment and annual collaboration fee. In addition, Grifols has committed to fund the development of immunoglobulin eye drops through FDA approval, which will be managed collaboratively by Grifols and Selagine, including the clinical, manufacturing and regulatory activities required for FDA approval for dry eye disease indication. In February 2023, Aldeyra Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (N … ebruary 2023, Novaliq, announced its plans for filing a Marketing Authorisation Application (MAA) for CyclASol® (ciclosporin ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment of dry eye disease (DED) in the European Union. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) determined that CyclASol® is eligible to be reviewed in a centralized procedure to receive a Union Marketing Authorisation f … egeneration. Under the terms of the agreement, Ocular Therapeutix has agreed to fund the research performed under the collaboration and retains all program inventions and associated intellectual property. , and entered into strategic discovery targeting the treatment of dry age-related macular degeneration. Under the terms of the agreement, Ocular Therapeutix has agreed to fund the research performed under the collaboration and retains all program inventions and associated in
ORCID Please enable JavaScript to continue using this application.
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Young Investigators Research Symposium Showcases Cutting-Edge Studies – Infectious Diseases Research Collaboration (IDRC) Home About About IDRC Board of Directors Senior Management Team Our Partners Policies & Resources Where We Work Projects Facilities & Infrastructure Publications News Opportunities Bids & Tenders Careers Fellowships Contact Donate News Young Investigators Research Symposium Showcases Cutting-Edge Studies August 13, 2024 The Infectious Diseases Research Collaboration (IDRC) hosted the Young Investigators Research Symposium on July 10, 2024. … ht against malaria. Dr Stephen Tukwasibwe was awarded the Distinguished Scholar Award for his exceptional contributions to malaria research spanning drug resistance and immunology domains. Dr Stephen Tukwasibwe proudly holds the Distinguished Scholar Award recognising his exceptional contributions to malaria research The New Investigator Award was also presented to Mr Thomas Katairo, recognising his promising research in malaria genomics. The awards underscored the exceptiona … alth initiatives. Thomas Katairo proudly holds the prestigious New Investigator Award, celebrating his innovative work and promising contributions to malaria research. As the symposium ended, the organisers thanked all participants for their invaluable contributions and collaboration in advancing scientific knowledge and strategies to combat malaria effectively. The event stood as a testament to the collective effort and dedication towards overcoming the challenges posed by m
Katairo GmbH - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners with Versant Ventures to Launch Saturnus Bio Coulter Partners Places Vincent Metzler as CEO of Cellcolabs Europe Unveils a Record 35 New Nvidia AI Sup … rapeutics Raises $5m Investment Led by Daphni Kos Biotechnology Partners: First Fund Reaches $123m Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events European Spatial Computing Healthcare Summit 2026 Leipzig EUROMAR … holm (NLSDays 2026) BIO-Europe 2026 Cologne (Köln) » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
SPDX-License-Identifier: 0BSD --> Vérification de la connexion... Les robots IA perturbent le Web, JavaScript est nécessaire pour accéder à cette page. protégé par haphash
Katairo GmbH | BioRegio STERN | Wirtschaft weiterdenken Direkt zum Inhalt Navigation aktivieren/deaktivieren Suche Suche Main navigation Projects AIM MEDI4Future NAMWISE RehAllianCE STEP4NAMs SustainMed 2.0 SynergyHub4Health ZIM-network biohymed ZIM-network smart analytics project history Network Map Database entry Jobportal News News Events Competitions and prizes Newsletter Our offers Our events Einschnitte - Einblicke Viewpoint Medtech Summer reception Our services Science2Start Technology Transfer For founders Lab and office space Investing, promoting, financing About us Team Press Supervi … r made fundamental discoveries, for which he was awarded in 2012 the Innovation Award of bioregions in Germany. In November 2013 Katairo received the Orphan Medicinal Product Designation from the European Commission for the treatment of Stargardt disease with Remofuscin. Category Biotechnology Working areas Development, Pharmaceutics Year of foundation 2011 Contact Katairo GmbH Rosentalstr. 5 72070 Kusterdingen +49-7071-549 6182 [email protected] http://katairo.com/ Contact pe
Katairo Announces “Enrolment Completion”in STARTT Study of Remofuscin® | BioRegio STERN | Wirtschaft weiterdenken Direkt zum Inhalt Navigation aktivieren/deaktivieren Suche Suche Main navigation Projects AIM MEDI4Future NAMWISE RehAllianCE STEP4NAMs SustainMed 2.0 SynergyHub4Health ZIM-network biohymed ZIM-network smart analytics project history Network Map Database entry Jobportal News News Events Competitions and prizes Newsletter Our offers Our events Einschnitte - Einblicke Viewpoint Medtech Summer reception Our services Science2Start Technology Transfer For founders Lab and office space I … from the European Union’s Horizon 2020 Research and In- novation program under Grant Agreement No 779317 “Soraprazan - a new regenerative ther apy for Stargardt's disease”. The recipient of this grant is a consortium formed by the following institutions and principle investigators : Eberhard-Karls-Universität Tübingen, (Coordinator and trial site), Dr. Katarina Stingl Radboud University Medical Center, Nijmegen (trial site), Prof. Dr. Carel Hoyng Ospedale San Rafaele, Milano
News | Synovo LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . Skip to main conte … g into a 2 year clinical trial. This is one of the most effective uses of an EU grant that I have encountered. A great result also for Stargardt's patients. Although Stargardt's disease is caused by a known mutation, it has been difficult to address via conventional gene therapy because the ABCA gene is too long for the typical viral vectors. The Katairo approach of stimulating the reduction of lipofuscin aggregates could be useful also in other diseases where etiology is les
Legal Notice – Katairo Home Technology Development News EU Funding About Us Legal Notice Information pursuant to Sect. 5 German Telemedia Act (TMG) Katairo GmbH Rosentalstr. 5 72070 Tübingen Commercial Register: HRB B 736298 Registration court: Amtsgericht Stuttgart Represented by: Dr. Wolfgang Klein (Geschäftsführer / managing director) Contact E-mail: [email protected] No support, do not call! Medical questions cannot be answered at this phone number. Please use our newsletter to stay updated. +49 (0)70 71 549 61 82 VAT ID Sales tax identification number according to Sect. 27 a of the S
Katairo GmbH awarded orphan medicinal product designation by the EMA | BioRegio STERN | Wirtschaft weiterdenken Direkt zum Inhalt Navigation aktivieren/deaktivieren Suche Suche Main navigation Projects AIM MEDI4Future NAMWISE RehAllianCE STEP4NAMs SustainMed 2.0 SynergyHub4Health ZIM-network biohymed ZIM-network smart analytics project history Network Map Database entry Jobportal News News Events Competitions and prizes Newsletter Our offers Our events Einschnitte - Einblicke Viewpoint Medtech Summer reception Our services Science2Start Technology Transfer For founders Lab and office space Inv … form of age-related macular degeneration (AMD) was awarded the 2012 Innovation Award of the biotechnology regions in Germany. Dr. Wolfgang Klein, CEO of Katairo GmbH. / Photo: Katairo GmbH. BioRegio STERN Management GmbH Friedrichstraße 10, 70174 Stuttgart T +49-711-870354-0 [email protected] Footer Privacy Statement Imprint Social Linkedin YouTube RSS
Sustained High Prevalence of Multiple Antimalarial Drug Resistance Markers in Uganda in 2023-24 | medRxiv Skip to main content Home About Submit ALERTS / RSS Search for this keyword Advanced Search Sustained High Prevalence of Multiple Antimalarial Drug Resistance Markers in Uganda in 2023-24 View ORCID Profile Thomas Katairo , View ORCID Profile Victor Asua , View ORCID Profile Francis D. Semakuba , View ORCID Profile Bienvenu Nsengimaana , View ORCID Profile Shahiid Kiyaga , View ORCID Profile Nicholas Hathaway , View ORCID Profile Kathryn Murie , View ORCID Profile Stephen Tukwasibwe , View … file Catherine S. Maiteki , View ORCID Profile Jimmy Opigo , View ORCID Profile Grant Dorsey , View ORCID Profile Samuel L. Nsobya , View ORCID Profile Moses R. Kamya , View ORCID Profile Bosco B. Agaba , View ORCID Profile Isaac Ssewanyana , View ORCID Profile Bryan Greenhouse , View ORCID Profile Philip J. Rosenthal , View ORCID Profile Jessica Briggs , Melissa D. Conrad doi: https://doi.org/10.64898/2026.03.15.26348231 Thomas Katairo a Infectious Diseases Research Collabor … thor on PubMed Search for this author on this site ORCID record for Jimmy Opigo Grant Dorsey f University of California , San Francisco, USA Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Grant Dorsey Samuel L. Nsobya a Infectious Diseases Research Collaboration , Kampala, Uganda Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Samuel L. Nsobya … no role in study design, data collection and interpretation, or the decision to submit the work for publication. We thank Prof. David P. Katete, Dr. Daudi Jjingo and Prof. Moses Joloba for their extensive support during the implementation of the IMMRSE-U study. We also thank Kylie Hilton for developing data management tools. References ↵ Akilimali , Aymar , Charles Bisimwa , Abdullahi Tunde Aborode , Chrispin Biamba , Leonard Sironge , Alain Balume , Rahma Sayadi , et al. 202 … inden , Melissa D. Conrad , Jennifer Legac , Simon P. Kigozi , Moses R. Kamya , Grant Dorsey , Samuel L. Nsobya , and Philip J. Rosenthal . 2019 . “ Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda .” Antimicrobial Agents and Chemotherapy 63 ( 3 ). doi: 10.1128/AAC.01818-18 . OpenUrl Abstract / FREE Full Text ↵ Aydemir ,
Impact of COVID-19 on New - onset Type 1 diabetes mellitus: A six-year retrospective review from two Paediatric clinics, Kampala, Uganda Impact of COVID-19 on New - onset Type 1 diabetes mellitus: A six-year retrospective review from two Paediatric clinics, Kampala, Uganda PLoS One . 2026 Feb 5;21(2):e0341145. doi: 10.1371/journal.pone.0341145. eCollection 2026. Authors Rosemary Ahabwenki 1 , Thereza Piloya 1 , Flavia Namiiro 1 , Wani Muzeyi 1 , Catherine Nyangabyaki 2 , Thomas Katairo 3 , Aidah Namugumya 1 ,&
Technology – Katairo Home Technology Development News EU Funding About Us Technology The role of Lipofuscin in STGD and Dry AMD Lipofuscin is a metabolic waste product deposited during life in various non-dividing tissues of the body. The retinal pigment epithelium (RPE) is such a non-dividing cell layer in the back of the eye and it accumulates lipofuscin. Lipofuscin deposits in RPE cells together with drusen formation is one of the hallmarks of Stargardt disease (STGD) and dry age-related macular degeneration (dry AMD) pathogenesis. In human eyes, lipofuscin comes to occupy a sub
Performance of molecular inversion probe DR23K and Paragon MAD4HatTeR Amplicon sequencing panels for detection of Plasmodium falciparum mutations associated with antimalarial drug resistance | Malaria Journal | Springer Nature Link Skip to main content Advertisement BMC journals have moved to Springer Nature Link. Learn more about website changes. Account Menu Find a journal Publish with us Track your research Search Saved research Cart Home Malaria Journal Article Performance of molecular inversion probe DR23K and Paragon MAD 4 HatTeR Amplicon sequencing panels for detection of Plasmodium fal … le Download PDF Save article View saved research Malaria Journal Aims and scope Submit manuscript Performance of molecular inversion probe DR23K and Paragon MAD 4 HatTeR Amplicon sequencing panels for detection of Plasmodium falciparum mutations associated with antimalarial drug resistance Download PDF Thomas Katairo 1 , Victor Asua 1 , 2 , Bienvenu Nsengimaana 1 , Stephen Tukwasibwe 1 , 3 , 4 , Francis D. Semakuba 1 , Innocent Wiringilimaana 1 , Brian A. Kagurusi 1 , Carolin … data and the corresponding authors had final responsibility for the decision to submit for publication. Corresponding authors Correspondence to Jessica Briggs or Melissa D. Conrad . Ethics declarations Ethics approval and consent to participate This study was conducted with the approval of relevant Ethical Committee Reivew. All study participants provided informed consent for sample collection and for future use of biological specimens. Competing interests The authors declare
EU Report: US and China Rely Heavily on EU Supplies | Maqsud Aripov posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree t
CureVac: „In der Naivität liegt auch Kreativität“ - karriereführer Facebook Instagram Linkedin X Youtube Xing Webchannels Ärzte Bauingenieure Consulting Digital Frauen in Führungspositionen Informationstechnologie Ingenieure Künstliche Intelligenz Nachhaltigkeit Naturwissenschaften Neustart Recht Wirtschaftswissenschaften Interviews Podcasts Videos Bewerbung Jobmessen und Events Profile Stellenmarkt Chrashkurs Bewerbung Weiterbildung Hochschulprofile MBA, EMBA, MSc, LL.M. & Co. Arbeitsleben Einsteigen Aufsteigen Ausland Insights Inspiration Profile Jobs Apps & Mobile E-Paper Newslett
A possible cure for a potentially blinding disease | Soraprazan Project | Results in Brief | H2020 | CORDIS | European Commission Skip to main content (opens in new window) Log in Log in English en Select your language Close CORDIS languages: es español de Deutsch en English fr français it italiano pl polski Machine translation: This is a machine translation provided by the European Commission’s eTranslation service to help you understand this page. Please read the conditions of use . български español čeština dansk Deutsch eesti ελληνικά français Gaeilge hrvatski italiano latviešu lietuvių ma … candidate’s safety and efficacy. “Our tests, which were the longest continuous application of our drug candidate in humans to date, showed good tolerability,” he explains. “This finding allowed us to extend the duration of the treatment, and we hope to get even more telling results on the drug’s effectiveness soon.” Overcoming challenges Achieving this finding was anything but easy. For example, the project’s use of non-CE marked equipment to measure its primary end point ra … ease blindness Katairo Remofuscin clinical study Project Information Soraprazan Grant agreement ID: 779317 (opens in new window) Project website This website may no longer be available or may not contain the original content. Please confirm that you want to visit {{ url }} Open URL Cancel DOI Each project (from H2020 onwards) is attributed a Digital Object Identifier (DOI) 10.3030/779317 Project closed EC signature date 15 November 2017 Start date 1 December 2017 End date 30 … he sum of the EU contributions of all participants in a project is equal to the grant amount. € 5 792 425,00 5 792 425,00 Coordinated by EBERHARD KARLS UNIVERSITAET TUEBINGEN Germany Download Download the content of the page XML PDF Last update: 22 April 2022 Booklet My Booklet Permalink: https://cordis.europa.eu/article/id/436250-a-possible-cure-for-a-potentially-blinding-disease European Union, 2026 CORDIS - EU research results This website is managed by the Publications Of
Innovationspreis der BioRegionen verliehen Direkt zum Inhaltsbereich Anmelden Suche Suchbegriffe eingeben Menü Nachrichten Medizin Politik & Debatte Praxis & Wirtschaft Panorama Regionen Specials Kongresse Kooperationen Sonderberichte Podcasts E-Paper Jobbörse Newsletter Verlag Mediadaten Rubrikanzeigen Abonnements Nachrichten Medizin Praxiswissen Podcasts Specials Kooperationen Regionen Politik & Debatte Sonderberichte Newsletter Jobbörse Startseite Praxis & Wirtschaft Unternehmen Innovationspreis der BioRegionen verliehen FRANKFURT/MAIN (maw). Professor Ulrich Schra
Katairo News - LARVOL Sigma Companies / Products / Mechanisms of Action / Diseases / Investigators / Non product trials --> Companies / Products / Mechanisms of Action / Diseases / Investigators --> Diseases Companies Products Productz Mechanisms of Action Sites --> Sites Katairo Welcome, Profile Billing Logout Products Diseases Products Trials News | ||||||||| Remofuscin (soraprazan) / Katairo Journal:& … an) / Katairo Journal: Mesopic microperimetry in Stargardt disease: Application and reliability. (Pubmed Central) - Jan 29, 2026 A parafoveal ring strategy may improve reliability but requires validation. Limiting test duration to ?450?seconds and comprehensive operator training are recommended to minimise potential bias. | ||||||||| Remofuscin (soraprazan) / Katairo , famotidine / Generic mfg. Journal: V
Lipofuscin Accumulation into and Clearance from Retinal Pigment Epithelium Lysosomes: Physiopathology and Emerging Therapeutics | IntechOpen Books Book Series Journals Publish About News Author Panel Login Submit What is Open Access? Open Access is an initiative that aims to make scientific research freely available to all. To date our community has made over 100 million downloads. It’s based on principles of collaboration, unobstructed discovery, and, most importantly, scientific progression. As PhD students, we found it difficult to access the research we needed, so we decided to create a ne … ors and editors from 3,291 institutions spanning 160 countries, including Nobel Prize winners and some of the world’s most-cited researchers. Publishing on IntechOpen allows authors to earn citations and find new collaborators, meaning more people see your work not only from your own field of study, but from other related fields too. Content Alerts Brief introduction to this section that descibes Open Access especially from an IntechOpen perspective How it Works Manage prefer … f RPE in visual-pigment regeneration In 1967, George Wald was awarded the Nobel Prize for revealing the essential role of Vitamin A for vision [ 3 ]. Vitamin A entirely is derived from the diet. A critical function of RPE cells is to supply the vitamin A-derived chromophore, 11-cis retinal, required for the light-sensing function of visual pigments to photoreceptor cells. Visual pigments are G-protein receptors (opsins) covalently linked to 11-cis-retinal. Opsins cannot respo … ofuscin accumulation. Advertisement Acknowledgments This study was supported by grant R01 EY027422 from NIH and BrightFocus Foundation award M2016124 to M.M.N, by grant RO1 EY08538 to ERB and by Departmental grants from Research to Prevent Blindness Foundation and Dyson Foundation. References 1. Bok D. The retinal pigment epithelium: a versatile partner in vision, J. Cell Sci. 1993;189 LP-195 2. Streilein JW, Ma N, Wenkel H, Fong Ng T, Zamiri P. Immunobiology and privilege of … 10.1074/jbc.M112.439935 67. Mitter SK, Rao HV, Qi X, Cai J, Sugrue A, Dunn WA, Grant MB, Boulton ME. Autophagy in the retina: A potential role in age-related macular degeneration, In: LaVail MM, Ash JD, Anderson RE, Hollyfield JG, Grimm C (Eds.), Retinal Degenerative Diseases. Springer US: Boston, MA;2012: pp. 83-90. DOI: 10.1007/978-1-4614-0631
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Sustained High Prevalence of Multiple Antimalarial Drug Resistance Markers in Uganda in 2023-24 | medRxiv Skip to main content Home About Submit ALERTS / RSS Search for this keyword Advanced Search Sustained High Prevalence of Multiple Antimalarial Drug Resistance Markers in Uganda in 2023-24 View ORCID Profile Thomas Katairo , View ORCID Profile Victor Asua , View ORCID Profile Francis D. Semakuba , View ORCID Profile Bienvenu Nsengimaana , View ORCID Profile Shahiid Kiyaga , View ORCID Profile Nicholas Hathaway , View ORCID Profile Kathryn Murie , View ORCID Profile Stephen Tukwasibwe , View … file Catherine S. Maiteki , View ORCID Profile Jimmy Opigo , View ORCID Profile Grant Dorsey , View ORCID Profile Samuel L. Nsobya , View ORCID Profile Moses R. Kamya , View ORCID Profile Bosco B. Agaba , View ORCID Profile Isaac Ssewanyana , View ORCID Profile Bryan Greenhouse , View ORCID Profile Philip J. Rosenthal , View ORCID Profile Jessica Briggs , Melissa D. Conrad doi: https://doi.org/10.64898/2026.03.15.26348231 Thomas Katairo a Infectious Diseases Research Collabor … thor on PubMed Search for this author on this site ORCID record for Jimmy Opigo Grant Dorsey f University of California , San Francisco, USA Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Grant Dorsey Samuel L. Nsobya a Infectious Diseases Research Collaboration , Kampala, Uganda Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Samuel L. Nsobya … no role in study design, data collection and interpretation, or the decision to submit the work for publication. We thank Prof. David P. Katete, Dr. Daudi Jjingo and Prof. Moses Joloba for their extensive support during the implementation of the IMMRSE-U study. We also thank Kylie Hilton for developing data management tools. References ↵ Akilimali , Aymar , Charles Bisimwa , Abdullahi Tunde Aborode , Chrispin Biamba , Leonard Sironge , Alain Balume , Rahma Sayadi , et al. 202 … inden , Melissa D. Conrad , Jennifer Legac , Simon P. Kigozi , Moses R. Kamya , Grant Dorsey , Samuel L. Nsobya , and Philip J. Rosenthal . 2019 . “ Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda .” Antimicrobial Agents and Chemotherapy 63 ( 3 ). doi: 10.1128/AAC.01818-18 . OpenUrl Abstract / FREE Full Text ↵ Aydemir ,
Katairo GmbH, Tübingen, Amtsgericht Stuttgart HRB 736298: Netzwerk, Wirtschaftsinfos Home Premium Service Data Service Anmelden Premium Service Data Service Anmelden This page is also available in English: Switch to northdata.com | Hinweis nicht mehr anzeigen Die Suchmaschine für Unternehmensdaten in Europa Einfache Suche Power Suche Tipps & Tricks Die Hilfecenter-Artikel Alles über die Einfache Suche und Überblick zur Power Suche erklären, wie die Suchfunktionen genutzt werden können. Länderfilter Schränke die einfache Suche nach Unternehmen und Personen auf ein oder mehrere Länder an, in
Technology – Katairo Home Technology Development News EU Funding About Us Technology The role of Lipofuscin in STGD and Dry AMD Lipofuscin is a metabolic waste product deposited during life in various non-dividing tissues of the body. The retinal pigment epithelium (RPE) is such a non-dividing cell layer in the back of the eye and it accumulates lipofuscin. Lipofuscin deposits in RPE cells together with drusen formation is one of the hallmarks of Stargardt disease (STGD) and dry age-related macular degeneration (dry AMD) pathogenesis. In human eyes, lipofuscin comes to occupy a sub
%PDF-1.7 %���� 591 0 obj >/Metadata 288 0 R/OCProperties >/OCGs[75 0 R 101 0 R 129 0 R 176 0 R 197 0 R 232 0 R 250 0 R]>>/Outlines 329 0 R/Pages 590 0 R/StructTreeRoot 350 0 R/Type/Catalog>> endobj 288 0 obj >stream 2026-06-26T19:12:22-07:00 2025-12-12T16:09:39-06:00 2026-06-26T19:12:22-07:00 Adobe Acrobat (32-bit) 25.1.20997 application/pdf Melissa Rosenthal uuid:a7ed2d8a-d2fc-4660-825c-f56ec276989f uuid:c073619f-1dd1-11b2-0a00-6a004882e8ff Adobe Acrobat (32-bit) 25.1.20997 endstream endobj 329 0 obj > endobj 590 0 obj > endobj 350 0 obj > endobj 333 0 obj > endobj 351 0 obj > endobj 352 0 ob … 08-19T13:58:29-05:00 2025-08-19T14:00:09-05:00 Adobe Illustrator 29.4 (Windows) application/pdf Figure 1 uuid:e62646e6-5ea1-4c61-975a-689aa26e6447 uuid:b24c4e25-7262-4b2f-8f4d-baf4f9f1d3f3 Adobe PDF library 17.00 endstream endobj 79 0 obj > endobj 72 0 obj >/Resources >/Font >/ProcSet[/PDF/Text]/Properties >>>/Rotate 0/Thumb 73 0 R/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>> endobj 99 0 obj >/Resources >/Font >/ProcSet[/PDF/Text]/Properties >>>/Rotate 0/Thumb 100 0 R/TrimBox[0.0
Thomas Katairo - MUJHU Research Collaboration Engage Donate Contact Us Home Who We Are About Us Strategic Plan Board of Directors Senior Management Investigators Early Career Investigators What We Do Research Programs Data Management DXA Services Capacity Building Community Engagement Corporate Social Responsibility Digital Library Annual Reports Policies Publications Conference Posters and Presentations News and Events News Stakeholder Meetings Media Gallery Events Opportunities Careers Tenders (+256) 200 404 100 [email protected] Upper Mulago Hill Road, P.O. Box 23491 Kampala, Ug
Roland Mirow - Business Development - Katairo GmbH | XING Navigation überspringen Jobs finden Unternehmen Netzwerk Insights Suche Anmelden Job posten Stellenanzeige schalten Produkte Roland Mirow Katairo GmbH Business Development München Roland Mirow Basis Ganzes Profil ansehen Selbstständig, Business Development, Katairo GmbH München , Deutschland Logg Dich ein, um alle Einträge zu sehen. Fähigkeiten und Kenntnisse Logg Dich jetzt ein, um das ganze Profil zu sehen. Berater der internationalen Pharmaindustrie mit Sc Marketing Vertrieb Funktionale Erfahrung in Unternehmenss operationellem Manag
%PDF-1.7 %���� 31 0 obj > stream x��}[�d���{��|���]}Y���?mI���� k�|�$��U�Y�ճ�֨���yx���q����i����Y���=}���_��5� m8�t�h���)�~������/�w.��I���c4�9d�N�������/~��߹ӟ��S>o�n�fh֟��vN�ӯ�~5���ɞ�1�� .��c_�h�l��?�sJv��0 ��ߡic�_7�d�9E��fυw�0� ϦxZ*�����|�!�r��듧)C�R ��Q;�kig�f��x0� ��'~��T��d�B�t# 2�-�+`��^0���t \�Λ� c؝]�0�`7�`�� ;��\�}}�g� ��QBCN8 M�#OHCX$3��e\Z%n�b8'g�?=��c�j�c�c�h�� �v3��v�4��韞2�� y��p�ƶs�Q�\��Šĝ� � �� � �g�0�?)�MÄ�~��R� �^�h�DZK�B�w�G��B� 6 � �lmr��6��4��&�ȃ9ZC� �c B��%�I �7�'p���� �'�c>;��И56������ͅR���Վ��ٗ�s ��%�)I A�@_M�xL&�j
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
%PDF-1.7 %���� 1563 0 obj > endobj 1595 0 obj >/Filter/FlateDecode/ID[ ]/Index[1563 97]/Info 1562 0 R/Length 149/Prev 10915872/Root 1564 0 R/Size 1660/Type/XRef/W[1 3 1]>>stream h�bbd```b``����@$���0��`q�� �m*�\ V�&����`�`�&X�=�iv`90�D�{�Hg��&;A��(�d�{�> D:���$�RD��Ej@�'� ";���_� L� l�@"@3�6)�`���?ß��y�] endstream endobj startxref 0 %%EOF 1659 0 obj >stream h�b```a``�e`e`04ec@1�P��D�� # o��]�-�7Q��r�+�]n\`�r�=� d %�y������ &��:5�Q� �[�3\��d#��E�Ɂ�� ��e1Xm�$�i*����#ω�J��DDB��q �X�02X:SS��5���� ��4=� �k�O'K�.� NkN�Z�����zԮ����k� Z��X���pP��]�&L … ^2�ᶰ�}�����r= d~��~ Ť|�OÍ#M��7^1�ᶰ�}�������k�G�C�m�'�� |5'�5�о���w/�.>RFp�=��>#��5�g x~a���o� n4/�k%���J>�#vg�z���&����/̿�6���B�~��\ �������ug�/��c�1�ܑ��9��~3'�>3x�ǿ�f�%1�;�M���6Ȓ���p���|��|O���;���!)���,�|:��D����{�&�g�(���o ~�Z����{K_* ���p'ǚ� ���� x#I�2�����u)�èo�_���v���i^5�eW��t��be9��6?Z��'�t� �3J�({}R�+�YNxu�ֆ���i|���r���B��+�*"�K `hjZ���a>��\�6��4��� ���O��5 B�I��S�nV{x�I�s������_5\�H� O~� ~���� �y!�ĺm���H˨���g����>'����o��^%�- … 2 ��t��}���+�6�� |C�,4���Eq C���6ي�'�cܩ��~� �P+� �: &��:����6� 6~x2G��rFPz��S�[��h�&��om��X%�ս�%�2�9 F}�Ezmt�QEQEQEQEQEQEQEQEQ_1����T���/��_A�� �No�,���ڟ�7��L�� �=�������}QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE�O��I�8��(W�?�Lo�'�&����_d��1�����É���}7_M��tQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE�|i��῁��O��k��m�U�%s��A Jߢ��c�O�? ��E���0�X4� hz��+��ZV� �s ~)�o��/�d����x[@��u \�,PB … \K�^ .iD�_ڠ�1 ���9#(�;��~� h_���c� � ��1|T��ߊ���4�?e (��T�:\҉|��A4b���rFPwn��>�п�b/���??g�b�����u�h�'�~� �l�uOگ�&���Ű��� ~��f�@�om���͂��M�t}���{Gh�[K��'+��Ώ���o�����wT���a�i_ �l�uOگ�&���Ű��� ~��f�@�om���͂��M�t}���{Gh�[K��'+���� |���?jo�!���6>~ɟ�>#|Qբ�~#[�K�)�xG�on�� ڬO���)hb�&h�$�V�'YGϟ�����M�=_�&���3�@��o�:�ZO�k �7o�����!�U����- ^D� �� ���(���)��߈ZO��w�*|-��O ��z~��x�Q��Bɢ�xz��o6*�xh�m�� ~��|G�}kƿ �ҿ���K��㿂>x�J�g�'� ���h�t�� … 5W0P045�P02T����+�-���(�����]�K �� � L endstream endobj 124 0 obj >stream application/pdf 10.1016/j.preteyeres.2024.101243 Elsevier Ltd Progress in Retinal and Eye Research, 99 (2024) 101243. doi:10.1016/j.preteyeres.2024.101243 Investing in vision: Innovation in retinal therapeutics and the influence on venture capital investment Dmitrij H
Thomas Katairo - Liverpool School of Tropical Medicine Skip to main navigation Skip to search Skip to main content Liverpool School of Tropical Medicine Home Search content at Liverpool School of Tropical Medicine Home Profiles Research units Research output Datasets Student theses © Images are the property of LSTM and may be protected by copyright and other laws. View Scopus Profile Mr. Thomas Katairo PhD , Faculty of Education PhD , Tropical Disease Biology Email thomas.katairo lstmed.ac uk Overview Fingerprint Network Research output (32) Similar Profiles (1) Personal profile Fingerpri … similar technologies. For all open access content, the relevant licensing terms apply We use cookies to help provide and enhance our service and tailor content. By continuing you agree to the use of cookies Log in to Pure Link opens in a new tab Liverpool School of Tropical Medicine data protection policy Link opens in a new tab About web accessibility Link opens in a new tab Report vulnerability Link opens in a new tab Contact us
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
About Us – Katairo Home Technology Development News EU Funding About Us About Katairo Team Katairo’s developments are driven by a dedicated team of experts in the field of drug development and biotechnology. Dr. Wolfgang Klein, CEO is an entrepreneur, executive, and investor in the biotech industry. In 2002, he joined the mRNA pioneer CureVac as CFO and Head of HR. He is co-founder and founding CEO of Katairo. Dr. Mario Fsadni, Acting Medical Director His experience includes >25 years of industrial ophthalmic drug development where he was Director ophthalmology product developme
3 German biotech companies took 51% of all VC funding in 2024. In 2025, the same three took 72%. 💰 💰 💰 In April 2026, one of them — Tubulis — was acquired by Gilead for up to $5 billion. 🚀 At… | Ellen Goel | 13 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your ch
VentureRadar 0){if($('#i_b_toggleMore').hasClass('active')){Search_Elastic();}else{Search_DeconstructSearchString();Search_Elastic(false);event.preventDefault();}}else{event.preventDefault();}}" onclick="this.removeAttribute('readonly');" ontouchstart="this.removeAttribute('readonly');" id="i_t_Search" name="VRSearch" readonly> All Ranked Organisation Names Apps and Links Homepage (myVR) Funding Deals Hub Similar Companies App Articles Manage Account Logout Login Free Sign-up Forgotten your password? By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie … de Therapies; Vaccines; Biotech Show more Show less Updates All Funding Insight Grant Award Conference Competition Research Website Traffic Trend Business InsighT 01 Dec 2020 Website traffic has increased in the past 3 months, up from a ranking of 676,733 to 376,314. Source: Data from alexa.com COVID-19 vaccine tracker - London School of Hygiene & Tropical Medicine Research Report 20 Sep 2020 [BioNTech; Fosun Pharma; Pfizer] listed among those developing/researching a COVID-1 … ene therapy to cost $850,000 per patient | Reuters Source: reuters.com The STEP Award (2011) Award 29 Nov 2011 Category Winner: Finances Source: The STEP Award (2011) Show less Funding Signals VENTURE FUNDED Venture-funding News Venture-funding News Venture-funding News Related Top Ranked Companies Lists Life Sciences Biologics Healthtech Sars-Cov-2 Vaccine Cancer Melanoma Immunotherapy Diagnostics Dna Rna Peptide Therapies Vaccines Biotech Website Archive 2022 2023 2024 2025 … search results. Please select a Type Funding Round Team Products & Technologies Grant Award Conference Competition Other {DETAIL_VALUE} Remove Upgrade for full access You have reached your free usage limit for today. Upgrade to a paid plan for: Unlimited search alerts 250 records per export Unlimited pages and searches Full Access from $ 60.00 per month Upgrade Now Your VentureRadar Business account is now active and your account information has been sent to … nditions Privacy Policy Cookie Policy Contact Us Twitter LinkedIn | Submit a Company Directory of Companies Login Free Sign-up for VentureRadar access or By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie Policy . Free Sign-up for VentureRadar access You must have cookies enabled to create an accou
%PDF-1.4 %���� 1 0 obj >/Metadata 2 0 R/Names 14 0 R/Outlines 15 0 R/Pages 3 0 R/StructTreeRoot 16 0 R/Type/Catalog/ViewerPreferences >>> endobj 2 0 obj >stream 10.1371/journal.pone.0341145 application/pdf Impact of COVID-19 on New – onset Type 1 diabetes mellitus: A six-year retrospective review from two Paediatric clinics, Kampala, Uganda Rosemary Ahabwenki Thereza Piloya Flavia Namiiro Wani Muzeyi Catherine Nyangabyaki Thomas Katairo Aidah Namugumya Joan Nakimera Fred Kyekulidde Robert Kidega Fozia Nizar Ali Angella Mirembe Bernard Kikaire Grace Ndeezi Victor Musiime Sarah Kiguli 2026-01-31 … 27e6d46946 xmp.id:3e4dae56-f1d2-a149-a602-9d603e46e463 proof:pdf converted from application/x-indesign to application/pdf Adobe InDesign 15.1 (Windows) / 2026-01-31T15:37:42+05:30 xmp.iid:7f49ed73-871c-1545-bfdc-0542fae0811c xmp.did:e08c2dbb-7de1-a84a-b8cc-c5eb16b92dc3 xmp.did:253a3229-8a74-6d4f-a0a5-4027e6d46946 default 2026-02-05 false 10.1371/journal.pone.0341145 www.plosone.org 10.1371/journal.pone.0341145 2026-02-05 false PStill version 1.84.42 www.plosone.org 10.1371/jo … se 113.515000 54.895056 Points Cyan Magenta Yellow Black Default Swatch Group 0 application/postscript Uma Maheswari R Adobe Illustrator Artwork endstream endobj 514 0 obj > endobj 526 0 obj > endobj 527 0 obj > endobj 570 0 obj >stream Adobe Illustrator CS5.1 2018-03-20T17:15:44+05:30 2018-03-20T17:15:44+05:30 2018-03-20T17:15:44+05:30 1 False False 210.001308 297.000304 Millimeters Cyan Magenta Yellow Default Swatch Group 0 application/postscript Uma Maheswari R orcid.eps x … 83052257CD1C 2018-03-20T17:15:44+05:30 Adobe Illustrator CS5.1 / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator endstream endobj 569 0 obj >stream Adobe … se 210.001308 297.000304 Millimeters Cyan Magenta Yellow Default Swatch Group 0 application/postscript Uma Maheswari R orcid.eps xmp.did:2EECDEB82D2CE811981583052257CD1C xmp.iid:2EECDEB82D2CE811981583052257CD1C xmp.did:2EECDEB82D2CE811981583052257CD1C saved xmp.iid:2EECDEB82D2CE811981583052257CD1C 2018-03-20T17:15:44+05:30 Adobe Illustrator CS5.1
Unmasking Asymptomatic Malaria: The Role of Acquired Immunity and Integrated Interventions in Sustained Transmission Control | Sciety Skip navigation Search Sciety application settings Home Groups Explore Newsletter About Log In Unmasking Asymptomatic Malaria: The Role of Acquired Immunity and Integrated Interventions in Sustained Transmission Control Hemaho B. Taboe Megan Sin Afsana Yesmin Eric Van Amber Olivia Prosper Feldman Ruijun Zhao Calistus N Ngonghala Read the full article See related articles Discuss this preprint Start a discussion What are Sciety discussions? Listed in This article
EY-Biotech-Report_D_2013 DE English Deutsch Français Español Português Italiano Român Nederlands Latina Dansk Svenska Norsk Magyar Bahasa Indonesia Türkçe Suomi Latvian Lithuanian český русский български العربية Unknown Einloggen bei YUMPU News Einloggen bei YUMPU Publishing TESTE ADFREE Entdecken Produkte Zeitschriften lesen e-Paper erstellen Prospekte lesen Magazine ePaper erstellen Einloggen bei YUMPU News Einloggen bei YUMPU Publishing × Achtung! Ihr ePaper wartet auf Veröffentlichung! Durch Aktivierung des Dokuments werden die Inhalte via KI optimal bei Google indexiert und für über … 72 und 73: Finanzierung Risikokapitalfinanzier Seite 74 und 75: Der AMD Therapy Fund, in dessen Inv Seite 76 und 77: Ausländische VC-Investoren nach wi Seite 78 und 79: Honigbienen und Milchkrautwanzen ü Seite 80 und 81: Finanzierung über strategische Inv Seite 82 und 83: CRO Services: Ein alternatives Fina Seite 84 und 85: Eigenkapitalfinanzierung in europä Seite 86 und 87: Finanzierung Finanzierungsquellen p Seite 88 und 89: Wichtigste Geldgeber in diese neuen Seite 90 und
Gametocyte production and infectivity among Ugandan malaria patients infected with P. falciparum with partial resistance to artemisinins | medRxiv Skip to main content Home About Submit ALERTS / RSS Search for this keyword Advanced Search Gametocyte production and infectivity among Ugandan malaria patients infected with P. falciparum with partial resistance to artemisinins Daniel Ayo , Sara Lynn Blanken , Ismail Onyige , Eric Musasizi , Nicholas Proellochs , Thomas Katairo , Shahiid Kiyaga , Bienvenu Nsengimaana , Innocent Wiringlimanna , Francis D. Semakumba , Isaac Ssewanyana , Kjerstin Lank … Okot , Bryan Greenhouse , Liusheng Huang , Jessica Briggs , Laura E. de Vries , Grant Dorsey , Chris Drakeley , Philip J. Rosenthal , Melissa D. Conrad , Emmanuel Arinaitwe , Maurice Okao , View ORCID Profile Teun Bousema doi: https://doi.org/10.64898/2026.04.09.26350477 Daniel Ayo 1 Infectious Diseases Research Collaborations , Kampala, Uganda 2 Department of Medical Microbiology, Radboud University Medical Centre , Nijmegen, The Netherlands Find this author on Google Schola … n Google Scholar Find this author on PubMed Search for this author on this site Grant Dorsey 7 Department of Medicine, San Francisco General Hospital, University of California , San Francisco, CA, USA Find this author on Google Scholar Find this author on PubMed Search for this author on this site Chris Drakeley 8 Department of Immunology & Infection, London School of Hygiene and Tropical Medicine Find this author on Google Scholar Find this author on PubMed Search for this a … esign, the collection, analysis, and interpretation of data, or the decision to submit findings for publication. RESULTS Between May 2023 and June 2024, we enrolled 235 patients with uncomplicated malaria. Infection with P. falciparum was confirmed by microscopy in 99.6% (234/235) of patients; one patient was positive by Rapid Diagnostic Test, negative by microscopy, but P. falciparum positive by molecular methods. The median age of patients was 13 years (IQR: 6–19), and medi … in an online repository upon publication. FUNDING This work was supported by a fellowship from the Netherlands Organization for Scientific Research (Vici fellowship NWO 09150182210039). There was additional financial support from the National Institutes of Health (grant numbers AI089674 International Centers of Excellence in Malaria Research Pro
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
US20250144075A1 - Melanin for treating lipofuscin-associated diseases - Google Patents US20250144075A1 - Melanin for treating lipofuscin-associated diseases - Google Patents Melanin for treating lipofuscin-associated diseases Download PDF Info Publication number US20250144075A1 US20250144075A1 US18/837,398 US202318837398A US2025144075A1 US 20250144075 A1 US20250144075 A1 US 20250144075A1 US 202318837398 A US202318837398 A US 202318837398A US 2025144075 A1 US2025144075 A1 US 2025144075A1 Authority US United States Prior art keywords lipofuscin melanin composition disease rpe Prior art date 2022 … s and makes no representation as to the accuracy of the status listed.) Pending Application number US18/837,398 Other languages English ( en ) Inventor Ulrich Schraermeyer Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) KATAIRO GmbH Original Assignee KATAIRO GmbH Priority date (The priority date is an assumption and is not a legal conclusion. Google has … sted.) 2022-02-09 Filing date 2023-02-09 Publication date 2025-05-08 2023-02-09 Application filed by KATAIRO GmbH filed Critical KATAIRO GmbH 2025-05-08 Publication of US20250144075A1 publication Critical patent/US20250144075A1/en Status Pending legal-status Critical Current Links USPTO USPTO PatentCenter USPTO Assignment Espacenet Global Dossier Discuss Images Classifications A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K — PREPARAT … l physical form A61K9/0012 — Galenical forms characterised by the site of application A61K9/0048 — Eye, e.g. artificial tears A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE A61P — SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS A61P27/00 — Drugs for disorders of the senses A61P27/02 — Ophthalmic agents A — HUMAN NECESSITIES A01 — AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUN … ated diseases Pending US20250144075A1 ( en ) Applications Claiming Priority (2) Application Number Priority Date Filing Date Title PCT/EP2022/053137 WO2023151788A1 ( fr ) 2022-02-09 2022-02-09 Mélanine pour le traitement de maladies associées à la lipofuscine PCT/EP2023/053262 WO2023152263A1 ( fr ) 2022-02-09 2023-02-09 Mélanine destinée au trait
Update on the Management of ABCA4 Retinopathy (Stargardt Disease) | Ophthalmology and Therapy | Springer Nature Link Skip to main content Advertisement Account Menu Find a journal Publish with us Track your research Search Saved research Cart Home Ophthalmology and Therapy Article Update on the Management of ABCA4 Retinopathy (Stargardt Disease) SYSTEMATIC REVIEW Open access Published: 04 June 2026 ( 2026 ) Cite this article You have full access to this open access article Download PDF Save article View saved research Ophthalmology and Therapy Aims and scope Submit manuscript Update on the Man … ilute treatment signals unless trials enrich for specific stages/phenotypes and apply sensitive endpoints. Accurate assessment of treatment response in ABCA4 retinopathy requires a rigorous, multimodal monitoring strategy, reflecting the disease’s slow progression, spatial heterogeneity, and evolving therapeutic goals. As interventions increasingly aim to modify disease biology rather than provide symptomatic benefit, emphasis has shifted toward objective biomarkers capable o
%PDF-1.5 %���� 1 0 obj >>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 13 0 R 16 0 R 17 0 R 18 0 R 24 0 R 25 0 R 26 0 R 27 0 R 28 0 R 29 0 R 30 0 R 32 0 R 33 0 R 34 0 R 35 0 R 37 0 R 38 0 R 39 0 R 40 0 R 41 0 R 43 0 R 44 0 R 46 0 R] /MediaBox[ 0 0 595.44 842.04] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��]�o7� ���~:H�z�|��( ؎Ӥ���b��{ d[~\cɵ��ҿ�8�r9��%�N� �ĝ�cf~�zp����^\n��;8�l��˫���l�🃳/˃�����bs�^ �>_lࣷ�����������ޫ�7� �l���z�)*�/)����h))/���^U� �����|V��S�����D>��ޫ�*N> � �7��}|No��7'��e��t>�4�gb��
Katairo - 2026 Company Profile, Team, Funding & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Corpo … Year 2011 Location Tubingen, Germany Stage Funding Raised Latest Funding Round Grant (prize money), Dec 01, 2017 , $***** Investors Europa Ranked 2399 th among 2631 active competitors Similar Companies Viridian Therapeutics & 281 more View Katairo's full profile Legal entities associated with Katairo Katairo is associated with 1 legal entit y given below: Legal Entity Name Date of Incorporation Revenue Latest Employee Count Documents Katairo Gmbh CIN: B2609_HRB73629 … estors Katairo has raised funding over 1 round . Its latest funding round was a Grant (prize money) round on Dec 01, 2017 for $ ***** . 1 investor participated in its latest round. Katairo has 1 institutional investor . Here is the list of recent funding rounds of Katairo : Date of Funding Funding Amount Round Name Post-Money Valuation Revenue Multiple Lead Investors Other Investors Dec 01, 2017 1303035 Grant (prize money) 9285518 8232625 9642600 1255286 Access funding benchm … tibodies & antibody-drug conjugates to treat cancer $146M CTI Life Sciences Fund , Advanced Biotechnologies Venture Fund ... & 16 others 71/100 2399th Katairo 2011 , Tubingen ( Germany ) , Funding Raised Developer of therapeutics for the treatment of disabling eye indications - Europa 22/100 Get insights and benchmarks for competitors of 2M+ companies! Sign up today! Looking for more details on Katairo 's competitors? Click here to see the top ones Katairo's … company, having raised a total of $ ***** in its 1st and only funding round , a Grant (prize money) round on Dec 01, 2017 . Where does Katairo rank among its competitors? Katairo ranks 2399th amongst 2631 active competitors , of which 905 are funded. It stands 11 th in terms of total funding among its competitors. The most recent competitors to r
Comprehensive analysis of molecular markers linked to antimalarial drug resistance in Plasmodium falciparum in Northern, Northeastern and Eastern Uganda BUSITEMA UNIVERSITY | LIBRARY Log in Submit an Item Browse Statistics English Català Čeština Deutsch Español Français Gàidhlig Italiano Latviešu Magyar Nederlands Polski Português Português do Brasil Suomi Svenska Türkçe Tiếng Việt Қазақ বাংলা हिंदी Ελληνικά Yкраї́нська Log In Email address Password Log in New user? Click here to register. Have you forgotten your password? Home Faculty of Health Sciences Department of Clinical Phamacolo … 1, Pfcrt dc.description.sponsorship Busitema University Research and Innovation Fund (BURIF) dc.identifier.citation Olupot-Olupot P, Paasi G, Katairo T, Alunyo JP, Nakiyemba A, Ocen GG, Pande S, Alaroker F, Okiror W, Ocen E, Oula A, Okalebo CB, Paul O, Amorut D, Tukwasibwe S, Ndidde SN, Sewanyana I, Nsobya SL. Comprehensive analysis of molecular markers linked to antimalarial drug resistance in Plasmodium falciparum in Northern, Northeastern and Eastern Uganda. Malar J. 2025
Lack of sponsorship shutters Chess players' dreams Close Support Us! Search for: Search Home AFCON 2025 Football Olympics Athletics Open dropdown menu Tusker Lite Rwenzori Marathon Rugby Open dropdown menu National 7s Africa 7s Motorsport Basketball Golf Open dropdown menu 2022 Tusker Malt Uganda Golf Open Cricket Op-Eds Boxing More Open dropdown menu Netball Volleyball Pool Hockey Weightlifting Chess Others Cycling Lacrosse Live Rowing Swimming Tennis STATS Open dropdown menu All Fixtures All Results AFCON 2025 Tables & Bracket Home AFCON 2025 Football Olympics Athletics Open dropdo
DevelopmentAid For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser .
%PDF-1.7 �������� 2 0 obj [/ICCBased 3 0 R] endobj 3 0 obj > stream x���wTS��Ͻ7�P����khRH �H�.*1 J��"6DTpDQ��2(���C��"��Q��D�qp�Id�y�͛� �~k����g�}ֺ����LX � �X��ň��g` �l�p��B�F�|،l���� ��*�?������Y"1P������\�8=W�%�Oɘ�4M�0J�"Y�2V�s�,[|��e9�2� �U�(j �MFk�����t,:��.FW��� ���8���c�1�L &���ӎ9�ƌa��X�:� � �r�bl1� {{{;�}�#�tp�8_\ �8��"�Ey�.,�X�����%�%Gщ1�-��9����Ҁ��K��l�.��oo���/�O$�&�'=JvMޞ x��ǥ��{��� �=Vs\�x� ��N柜>�u�����c�Kz=s�/�o�l����|ϝ���?y���� ��^d]��p�s�~��� : ;� ��/;]��7|����W����p�������Q�o�H�!�ɻ��V���sn��Ys}��ҽ����~4��]� =>�=:�`��;cܱ
EU Funding – Katairo Home Technology Development News EU Funding About Us EU Funding “SORAPRAZAN”: A STGD POC STUDY Together with a consortium of partners, Katairo has received funding from the European Commission. Under the project name “ Soraprazan ” – which is the INN name of the active ingredient of Remofuscin – a proof-of-concept clinical trial with Remofuscin for Stargardt disease is being prepared and performed. The project encompasses the manufacture of the drug product, including trial site supply, regulatory affairs, the planning and execution of t … nbsp;European Union’s Horizon 2020 research and innovation programme under grant agreement No 779317. If you are interested in updates on this program, please subscribe to our newsletter . Consortium The consortium includes the following partners. Eberhard-Karls-Universität Tübingen (coordinator, trial site) Leiden University Medical Center (trial site) Ospedale San Rafaele, Milano (trail site) Radboud University Medical Center, Nijmegen (trial site) Southhampton U
Katairo – therapeuticals in sight Home Technology Development News EU Funding About Us Drug development for seriously disabling eye indications Technology Remofuscin has the surprising characteristic of removing lipofuscin from living cells in the retinal pigment epithelium (RPE). This paradigm-breaking effect was previously believed to be impossible. Learn more Development Remofuscin is being developed for two indications: Stargardt disease and dry age-related macular degeneration. In both indications, Remofuscin is entering Phase 2. Learn more Sign up for our newsletter! For the purpos … n below. We use the external service Mailchimp to send our newsletter. When you submit the form, your data will be transferred to Mailchimp and processed there. You can unsubscribe from the newsletter at any time. See our privacy policy for more information. Sign up! Leave this field empty if you're human: Katairo GmbH Rosentalstr. 5 72070 Tübingen Germany [email protected] Navigation Home Technology Development News EU Funding About Us Information Legal Notice Privacy Po
Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study - Queen's University Belfast Skip to main navigation Skip to search Skip to main content Queen's University Belfast Home Help & FAQ Link opens in a new tab Search content at Queen's University Belfast Home Profiles Research units Research output Projects Impacts Datasets Activities Prizes Press/Media Student theses Equipment Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neova … speakers’ fees, consulting fees and travel support from Novartis and Bayer; NE: grant/research support from Novartis and Bayer; speakers’ honoraria from: Novartis, Bayer, Allergan and Heidelberg Engineering; Advisory board member for: Novartis, Bayer, Allergan, Bausch and Lomb, Alimera Sciences and Roche; consultancy fees from Bayer; FG: consultant for Novartis and Bayer; advisory board member for Novartis and Bayer; speakers’ fees and research support from Bayer; FGH: financ … Novartis and Eli Lilly; consultant for Hakko Kyowa and Circadian Therapeutics; grant/research support from Novartis; HE: travel grants and speakers’ fees from Novartis; advisory board member for Novartis; SG: speakers’ fees from Hoffman-La Roche and Novartis; advisory board member for, and travel grants from Bayer; DFG: travel grants from Novartis and Bayer; speakers’ fees from Novartis; RH: research support and travel grants from, and advisory board member for Novartis, Bay … n, and Ellex; AL: travel support to attend educational meetings from Bayer; NP: grant support and travel grants from Novartis and Bayer; PP: none declared; CS: speakers’ fees, consulting fees, conference and travel support from Novartis and Bayer; ST: travel grant and conference registration from Bayer; DV: travel grants from Novartis, Bayer and Allergan; Advisory board member for: Allergan, Novartis, Bayer, Alcon and Polyphotonix; investigator on clinical trials sponsored or … s and Bayer; MAW: travel grants from Novartis, Bayer and Allergan; recipient of grant to develop medical education material on ophthalmology; AW: consulting fees from Novartis and Bayer; speakers’ fees from Novartis; advisory board member for Novartis; travel grants from Bayer; research support from Novartis and Bayer; RHZ: none declared; FI: emp
%PDF-1.4 %���� 1 0 obj > endobj 6 0 obj > endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj > endobj 5 0 obj > endobj 7 0 obj > /Font 26 0 R >> /MediaBox [0.0 7.920007 1440.0 817.92] /Contents 27 0 R /StructParents 0 /Tabs /S /Parent 2 0 R /BleedBox [0.0 7.920007 1440.0 817.92] /TrimBox [0.0 7.920007 1440.0 817.92] /CropBox [0.0 7.920007 1440.0 817.92] /Rotate 0 /Annots [] >> endobj 8 0 obj > /Font 31 0 R >> /MediaBox [0.0 7.920007 1440.0 817.92] /Annots [32 0 R 33 0 R 34 0 R 35 0 R 36 0 R 37 0 R 38 0 R 39 0 R 40 0 R 41 0 R 42 0 R 43 0 R 44 0 R 45 0 R 46 0 R 47 0 R 48 0 R 49 0 R 50 0 R 51 0 R 5 … �]6��|�оP�Y�vVA^����� i�����Ku���C�e��d�=f 6NAa:�V��v��j6RP��ׂ����hu��RfP��,��H,Iփ�C��3�j_�t[������QE�Ԡ���?]r�)ImF�=A�� �0�Z�����5H�z��1�+/(X�ٶfE �+���@�X�u�_^mp`HL�� 65V=�5��ع��&��(uu-٥'#W�q��������B��Лf��*�N�����p�z�%��@ҁ�����-qK�k �h�x|І%пD\�!a�n�.Э���(q .�M���.H�����Ry^�_Jv��o�dkJ�z� |S`���sB�Y/��گ������s�ɘ�]�E��/8����W�`�j������.��� O�mY:�o��D|�MC�~��,����`� �i�IJӦF�tX�wӒR[�QC �#� �]^ ������:^�������W� �6 ��A�+��/���߄+5����_��
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
%PDF-1.7 �������� 2 0 obj [/ICCBased 3 0 R] endobj 3 0 obj > stream x���wTS��Ͻ7�P����khRH �H�.*1 J��"6DTpDQ��2(���C��"��Q��D�qp�Id�y�͛� �~k����g�}ֺ����LX � �X��ň��g` �l�p��B�F�|،l���� ��*�?������Y"1P������\�8=W�%�Oɘ�4M�0J�"Y�2V�s�,[|��e9�2� �U�(j �MFk�����t,:��.FW��� ���8���c�1�L &���ӎ9�ƌa��X�:� � �r�bl1� {{{;�}�#�tp�8_\ �8��"�Ey�.,�X�����%�%Gщ1�-��9����Ҁ��K��l�.��oo���/�O$�&�'=JvMޞ x��ǥ��{��� �=Vs\�x� ��N柜>�u�����c�Kz=s�/�o�l����|ϝ���?y���� ��^d]��p�s�~��� : ;� ��/;]��7|����W����p�������Q�o�H�!�ɻ��V���sn��Ys}��ҽ����~4��]� =>�=:�`��;cܱ